According to these results, we investigated the therapeutic interest of Chk1 and Wee1 inhibitors (AZD7762 and MK-1775) alone and in combination using our large collection of MM cell lines with different cytogenetic abnormalities (12, 13, 17). The gene discussed is CHEK1; the disease is Miyoshi myopathy.